d.planchard
@dplanchard
Followers
5,556
Following
208
Media
819
Statuses
1,914
Thoracic Oncologist - Prof at University Paris Saclay - Head of Thoracic Group and CICT, Medical Oncology Dpt- Gustave Roussy - Villejuif - France 🇫🇷
Joined July 2009
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Mother's Day
• 2156128 Tweets
Arsenal
• 538453 Tweets
Ángel
• 209581 Tweets
Travis
• 168200 Tweets
Cataluña
• 86422 Tweets
Spurs
• 86392 Tweets
Sarah
• 84942 Tweets
Racing
• 55788 Tweets
Illa
• 53989 Tweets
#Amici23
• 53671 Tweets
Pacers
• 42119 Tweets
The Knicks
• 35075 Tweets
Hawks
• 34768 Tweets
Vitória
• 34619 Tweets
Trae
• 34362 Tweets
Abel
• 27024 Tweets
#ConexiónHonduras10
• 23492 Tweets
Rony
• 23454 Tweets
الزمالك
• 22967 Tweets
Pistons
• 22434 Tweets
Costas
• 17938 Tweets
雨の月曜日
• 17758 Tweets
Veiga
• 17112 Tweets
Rory
• 12743 Tweets
Belgrano
• 12439 Tweets
土砂降り
• 11729 Tweets
Rossi
• 11127 Tweets
Jara
• 10760 Tweets
Proud to lead this publication with P.A.Janne and all the co-authors...thank you to the patients who actively participated in this research and enabled us to offer a new therapeutic option for our EGFRmut patients in 1st-line.
@NEJM
@DanaFarberNews
@GustaveRoussy
@CICThoraciques
8
31
164
Metastatic NSCLC ESMO Guidelines including some corrections
@Annals_Oncology
@myESMO
@peters_solange
5
79
133
Always impressed by the rapidity of tumor regression after only 1 injection of Datopotamab deruxtecan (ADC-anti Trop2) (ICARUS-Lung01trial
@GustaveRoussy
). NSCLC with an EGFRmut (Del19) after Osimertinib then Platinum-Pemetrexed-Pembrolizumab…
@CICThoraciques
1
27
129
What a great update of the 2023 metastatic non-oncogene addicted NSCLC
@myESMO
guideline. A pleasure to participate under the coordination of
@HendriksLizza
and
@MartinReck2
and with all experts
@APassaroMD
@peters_solange
@TonyMok9
@bensolomon1
@JessicaMenis
@SmitEgbert
…
0
41
112
Type of major tumor response that can be observed with Trastuzumab Deruxtecan in pts with HER2 mutated NSCLC...
@GustaveRoussy
#ASCO2020
1
27
103
1
35
104
7
7
101
I'm very proud of my appointment to this wonderful institution and faculty, and I'd like to thank the directors for their unfailing support!
@GustaveRoussy
@MedecineUPSay
@GroupeUnicancer
@barlesi
David Planchard, oncologue thoracique à
@GustaveRoussy
, est nommé Professeur associé auprès de l'
@UnivParisSaclay
par le Ministère de l'Enseignement Supérieur et de la Recherche (
@sup_recherche
).
Un grand bravo pour cette belle nomination ! 👏
🔗
8
3
75
18
1
101
IMbrave150, unresctable HCC, impressive results and new standard of care....
#ESMOAsia19
@myESMO
2
59
94
Impressive evolution of therapeutic options in squamous NSCLC with IO
@Annals_Oncology
@myESMO
@peters_solange
1
60
91
Neo vs Adjuvant Chemo IO…? Need more strategy studies in resected NSCLC…
#AACR2022
@nicogirardcurie
2
10
90
Dabrafenib+Trametinib confirms its place as standard therapy (1st or 2nd line, ORR: 63.9/68.4% and mPFS: 10.8/10.2 mo and mOS: 17.3/18.2 mo with 5-years rates 22/19%) in our BRAFV600E NSCLC pts. Update at 5years…
@JTOonline
#BRAF
@IASLC
1
24
91
Another impressive response after only a single injection of datopotamab deruxtecan (ICARUS lung trial
@GustaveRoussy
) of a pulmonary sarcomatoid carcinoma with multiple lung and bone metastases, evolving after chemotherapy and immunotherapy (3rd line)...
@CICThoraciques
3
20
87
First phase III to demonstrated significant OS improvement with 3nd generation EGFR TKI vs 1st generation (mOS: 38.6 vs 31.8mo) by
@RamalingamMD
#ESMO2019
.Osimertinib now as the preferred first line option for EGFRmut NSCLC. Great news for patients
@GustaveRoussy
1
37
84
An important piece of the puzzle for EGFR mut pts for which it is important in 2020 to have the reflex test for our resected NSCLC pts ...
@NEJM
@DrRoyHerbstYale
@GustaveRoussy
4
23
87
The race for KRAS G12C inhibition NSCLC is launched, results more than promising with Adagrasib presented by Pasi A Jänne
#ENASymp20
. Can't wait to have it ...
0
28
84
EGFRdel19 NSCLC in 4th line trtt post Osi, CT-IO, Gem after 1 injection of datopotamab deruxtecan (ADC-Trop2, ICARUS 01 lung trial) …
@GustaveRoussy
1
15
82
0
28
78
ESMO Class of 2022 Lung Preceptorship Paris 🇫🇷
@myESMO
THANK YOU and see you in 2023….
@peters_solange
@finn_corinne
@BenjaminBesseMD
@JordiRemon
@HendriksLizza
@TonyMok9
@barlesi
@APassaroMD
@DrSanjayPopat
@marinagarassino
1
10
76
Superb presentation by
@PamelaAbdayem
on ADCs pharmacology, a major topic in thoracic oncology
@wclc23
3
27
75
1
29
71
It's great to see Gustave Roussy ranked 3rd among hospitals for oncology... Congratulations to the teams for their work and efforts in a difficult period.
@Newsweek
@GustaveRoussy
@CICThoraciques
0
2
73
IO monotherapy still an excellent treatment option to avoid chemoT in NSQ-NSCLC PD-L1 high except in pts with no smoking history. Very nice presentation
@peters_solange
@myESMO
0
23
70
Impressive efficacy (ORR 64%) of Adagrasib in KRAS (G12C) pts with STK11 co-Mutation (potential predictor of resistance to IO). This underlines the importance of testing co-Mutations in large NGS panel in lung...
@DanaFarber
by Pasi A.Jänne
#ENA20
2
31
71
Major new drug for HER2 mut NSCLC. Interim analysis from phase 2 DESTINY-Lung01 will be presented during the ASCO20 Virtual meeting...
#Asco2020
0
13
64
Congratulations
@BenjaminBesseMD
for the superbe ESMO discussion on EGFRex20ins and RET NSCLC pointing on toxicities and difficulties to get access to those drugs without randomized trials in many countries…
@myESMO
#ESMO23
@GustaveRoussy
0
22
66
Clinically meaningful improvements in TDT, TFST, TDTKI and PSF2 with osimertinib vs comparator EGFR-TKI in FLAURA trial which provides further confidence in the encouraging interim OS data
@myESMO
#ESMOASIA2018
3
26
63
7
3
62
A important news after FLAURA trial ... Tagrisso - Adaura phase 3 trial to be unblinded early after overwhelming efficacy in adjuvant trtt of pts EGFRmut NSCLC...
@AstraZeneca
3
20
63
A big THANKS to ESMO
@myESMO
and all the speakers for this incredible preceptorship in Paris ! 2 days of great exchanges on thoracic oncology.
@peters_solange
@marinagarassino
@BenjaminBesseMD
@barlesi
@DrSanjayPopat
@TonyMok9
@HendriksLizza
@APassaroMD
@JordiRemon
@finn_corinne
2
8
64
Important practicing results for N2 lung cancer operated. No significant improvement DFS or OS in PORT arm and more toxicities to be explored
@GustaveRoussy
#ESMO2020
0
24
63
definitely a bad year ... I hope that in 2021 the ESMO will take place in Paris 🇫🇷 to celebrate the end of virtual discussions/meetings and enjoy good food with good friends from all over the world !
@myESMO
2
7
61
3
4
62
Proud to have with us these 2 new stars of thoracic oncology. An important strengh to remain a leading centre in the field and to pursue our research and objective of improving the management of our patients
@GustaveRoussy
@BenjaminBesseMD
@jsoriamd
@barlesi
2
7
60
Looking forward to this 1st ESMO Paris preceptorship in november 2022 on lung cancer with my colleagues/Friends
@barlesi
@peters_solange
@BenjaminBesseMD
A good reason to come back to Paris after esmo2022
@myESMO
@GustaveRoussy
@CICThoraciques
0
9
58
Reassuring to see in FLAURA2 on the first mutational analyses that resistance mechanisms are comparable in 2 arms and that exposure to chemoT does not induce new resistance mechanisms…and should not impact subsequent targeted 2nd line options
@myESMO
#esmoAsia23
1
23
57
Really happy to have met my friend Jordi in Lisbon ! No time to stay but he will give for sure a great lecture on EGFR pts....
@JordiRemon
2
2
56
1
3
57
Probably best way to detect NTRK gene fusion in lung pts RNA-NGS by L.Bubendorf
#ELCC19
@myESMO
@alexdrilon
2
19
54
Great news. Positive FLAURA2 phase III trial. Potential new treatment option 1st line EGFRmut pts ? Waiting to see the results presented.
2
20
54
Congratulations to
@barlesi
for this nomination and take over the position of Director from
@jsoriamd
Continuity is assured for
@GustaveRoussy
En tant que membre du conseil d'administration de l’Institut
@GustaveRoussy
, nous avons élu
@barlesi
comme nouveau Directeur Général. Je remercie chaleureusement
@jsoriamd
pour ses années de dévouement dans la lutte contre le cancer !
3
6
25
5
11
53
Practical questions with IO presented by
@barlesi
at
#ESMOAsia19
@myESMO
and clear messages, thank you !
1
34
48
BM strategy in EGFRmut pts remains a major challenge and being able to achieve 48% (vs 16%) complet CNS resp (+CNS PFS HR:0.40) with FLAURA2 regimen is potentially clinically impacting and should make us think about it in our choice of 1st line strategy.
@JCO_ASCO
@EGFRResisters
0
16
53
Lorlatinib in first line...impressive improvement of PFS and major brain efficacy but compared to crizotinib. Need further follow up for duration of response, PFS and toxicity....
#ESMO2020
0
14
50
A new standard of care for our HER2 patients, the ADC revolution in lung cancer after TKIs and immunotherapy !
#lungcancer
Phase II DESTINY-Lung02 Trial:
Trastuzumab deruxtecan (T-DXd) shows promising antitumor activity in HER2-mutant metastatic NSCLC patients. Confirmed ORR: 49% for 5.4 mg/kg & 56% for 6.4 mg/kg. Safety profile favors T-DXd 5.4 mg/kg. 🎯
#CancerResearch
#lungcancer
Pasi A. Jänne…
0
17
67
1
18
52
Important result awaiting in EGFR mut pts :OS of AURA3 trial : just confirm to use osimertinib first line
@myESMO
#esmoasia19
0
25
49
Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non–Small Cell Lung Cancer
4
20
51
Impressive work of all teams and unlimited support of our management to protect all staff and pts with maks at the entrance, systematic hand washing and personalized accompaniment of pts by restricting the accompanying persons...
@GustaveRoussy
2
15
47
Additional significant post-progression results, particularly wih PF2, before having mature OS data of osimertinib in first line EGFRm NSCLC (FLAURA trial)
@CCR_AACR
@AstraZenecaFR
@AstraZeneca
5
19
49
Recruitment of patients in phase III FLAURA2 will end soon. We look forward to seeing the first efficacy results after these very reassuring safety data of chemoT+Osi 1st line
@ESMO_Open
@myESMO
Online
@ESMO_Open
- safety lead-in of FLAURA2 (osimertinib + platinum doublet chemo. No unexpected safety signals. Await efficacy results - will the addition of chemo to osimertinib impact survival in
#EGFR
mutant NSCLC as it did with gefitinib?
#LCSM
3
15
60
0
8
50
Neoadj Nivolumab-ChemoT. Need to see long-term benefit (3Y, 5Y), OS and toxicities... Questionable benefit stages IB/II and PDL1 negative + EFS control arm rather low.
#AACR2022
3
17
49
Next step for osimertinib first line EGFRmut NSCLC to try to prevent resistance by P.A Janne
#JSMO
1
20
47
Great collaborative work to have this most important series of RET+ NSCLC patients from 31 cancer centers. Congratulations to M.Aldea and
@BenjaminBesseMD
for coordinating this RET-MAP study
@GustaveRoussy
@CICThoraciques
@JTOonline
RET-MAP study
@JTOonline
characterizes 218 pts with
#RET
fusion-positive NSCLC. 56% female, 93% adeno, 41% smokers, 72% with KIF5B. mTMB low (2.5 mt/Mb) and mPDL1 10%. CNS metastases in 21% at baseline, 31% overall. RR to chemo was 55% with mPFS 8.7m.
2
15
42
2
11
49
Always the most beautiful monument in the world !! Happy July 14 before tomorrow's final...🇫🇷🇫🇷🇫🇷
0
4
44
Great news and proud to have developed these new ESMO guideline (so much new treatments in lung cancer, it’s amazing !) with all the co-authors (thanks to all)
@DrSanjayPopat
@TonyMok9
@finn_corinne
@peters_solange
@myESMO
@Annals_Oncology
Just out: ESMO Clinical Practice Guidelines supplemt w/ 3 new GLs: Bone sarcoma, Metastatic NSCLC, Hepatocellular
@ERN_EURACAN
@SIOPEurope
@casali_pg
@dplanchard
@DrSanjayPopat
@TonyMok9
@peters_solange
@jeanyvesblay
@Annals_Oncology
#hpbcsm
#LCSM
#scmsm
0
34
51
2
18
46
And the most impressive on brain mets after C1 Datopotamab deruxtecan (EGFR del 19 4th line…) (ICARUS lung 01
@GustaveRoussy
)
0
9
46
Welcome to ESMO Academy 2022 in Dublin ! Great to be able to exchange with our young oncologists.
@myESMO
1
1
46
5-year barrier, still impressive the benefit of durvalumab which is maintained on PFS and OS in the pacific trial
#ASCO21
0
17
44
Great
@GustaveRoussy
post-ESMO21, to be found on YouTube ! Thanks to the master of ceremony Pr K.Fizazi. Join us for the lung session with
@BenjaminBesseMD
@CICThoraciques
📢📢 Retrouvez dès maintenant l’
#ESMO2021
décrypté par
@BenjaminBesseMD
et
@dplanchard
en direct sur YouTube :
0
2
10
1
5
44
Great to see our DIrector
@jsoriamd
@GustaveRoussy
presenting the innovation health 2030 strategy with our president
@EmmanuelMacron
Repositioning France as a competitor and leader in innovation and attractiveness! 🇫🇷
0
5
45
Impressive new therapeutic class in lung cancer with HER2, HER3, TROP2, CEACAM5, MET targets…
@LungCaJournal
@CICThoraciques
🌟 NEW IN
@LungCaJournal
:
Antibody-Drug Conjugates: A Promising Novel Therapeutic Approach in
#LungCancer
by
@ADesaiMD
@PamelaAbdayem
@DrAlexAdjei
&
@dplanchard
Don’t miss it 👇🏼
#LCSM
0
27
81
0
15
44
Great news, hopefully we can also move forward with EMA but probably not as fast unfortunately for our EGFR patients...
@AstraZeneca
@AstraZenecaFR
#EGFR
2
12
44
Nice lineup of speakers/colleagues/friends at this
@myESMO
Preceptorship
@finn_corinne
@peters_solange
@TonyMok9
@marinagarassino
1
2
44
Great lung session this morning with Solange and Raffaele. I hope our young colleagues enjoyed it! Amphitheater full, impressive and top organization by the ESMO staff. Always a pleasure to attend, thanks for the invitation.
@myESMO
@peters_solange
@caliraf
1
8
42
Gustave Roussy's unstoppable development, soon to have its own metro station (an architectural masterpiece)...can't wait for 2024/2025!
@GustaveRoussy
2
4
43
MET exon 14-altered lung cancers express PD-L1, but TMB is low and few responses to PD-1 blockade.
@Annals_Oncology
1
20
38
Again an impressive clinical benefit of lorlatinib in alk pretreated nsclc pts and ineteresting data on response and ctDNA mutation + tissu by
#AACR18
1
26
39
Molecular Tumor Board discussion during our annual
@GustaveRoussy
chemotherapy courses (15 days of update on all pathologies by our experts and more than 150 participants...).
@CICThoraciques
0
6
40
Olaparib maintenance in NSCLC by S.Postel-Vinay. Unfortunately desapointing results...waiting further translational research results
@GustaveRoussy
#ELCC21
0
14
37
Study of Japanese group (WJOG) informative to confirm that IO is not the best option for EGFRmut pts…
0
16
38
Nice work by Y-L Wu et al on Pan-Asian adapted ESMO Guidelines for management of metastatic NSCLC pts
@Annals_Oncology
@myESMO
0
17
39
Promising efficacy of 4th generation EGFR TKI after 3 weeks in NSCLC pt EGFR L858R, T790M, C797S mutations in progression post gefitinib, osimertinib and amivantamab...to be continued
@GustaveRoussy
@CICThoraciques
2
8
39
Japanese pts, nationwide genome screening program, really impressive ! by Dr Miyamoto
#ESMO2019
0
18
37
Congratulations to our new dean of the Paris-Saclay Faculty of Medicine Pr M.Humbert and we are very happy to continue our collaboration
@UnivParisSaclay
@GustaveRoussy
2
1
37
Important data on osimertinib in LM EGFRm T790M+ (retrospective trial), impressive results presentation by
@TonyMok9
@myESMO
#ESMOAsia18
0
12
36
Atezolizumab (IMpower 150) as a new PD-L1 option/standard in association with CT + bevacizumab in first line in non-sqamous NSCL pts not eligible for Pembro monotherapy ?
#esmo
4
16
36